Becton, Dickinson and Company Stock (NYSE:BDX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$238.22

52W Range

$218.75 - $269.52

50D Avg

$236.56

200D Avg

$236.71

Market Cap

$68.64B

Avg Vol (3M)

$1.39M

Beta

0.45

Div Yield

$3.80 (1.60%)

BDX Company Profile


Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

70,000

IPO Date

Feb 21, 1973

Website

BDX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 23Sep 22Sep 21
Medical$2.00B--
Life Sciences$2.30B--
Consumables$2.00B$1.90B$2.50B
Products and/or Services$2.30B$2.50B$2.10B

Fiscal year ends in Sep 23 | Currency in USD

BDX Financial Summary


Sep 23Sep 22Sep 21
Revenue$19.37B$18.87B$20.25B
Operating Income$2.11B$2.28B$2.80B
Net Income$1.48B$1.78B$2.09B
EBITDA$4.71B$4.60B$5.17B
Basic EPS$4.97$5.93$6.92
Diluted EPS$4.94$5.88$6.85

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Aug 01, 24 | 12:55 PM
Q2 24May 02, 24 | 12:00 AM
Q1 24Feb 01, 24 | 11:41 AM

Peer Comparison


TickerCompany
XRAYDENTSPLY SIRONA Inc.
COOThe Cooper Companies, Inc.
WSTWest Pharmaceutical Services, Inc.
RGENRepligen Corporation
HOLXHologic, Inc.
ALCAlcon Inc.
RMDResMed Inc.
ANGOAngioDynamics, Inc.
HAEHaemonetics Corporation
ICUIICU Medical, Inc.
TFXTeleflex Incorporated